Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
复制标题
FDG-PET在临床神经内分泌前列腺癌中的效用。
DOI：
10.1002/pros.22831
复制
发表时间：
2014-08
期刊：
影响因子：
2.8
通讯作者：
Osborne, Joseph R.
中科院分区：
文献类型：
--
作者：
Spratt, Daniel E.;Gavane, Somali;Tarlinton, Lisa;Fareedy, Shoaib B.;Doran, Michael G.;Zelefsky, Michael J.;Osborne, Joseph R.
氟代脱氧葡萄糖（FDG）正电子发射断层扫描（PET）在前列腺腺癌（PCA）中具有明显的局限性。然而，评估PET在神经内分泌前列腺癌（NEPC）中的效用的数据仅限于孤立的病例报告。在此，我们描述了第一个病例系列，以评估FDG-PET在NEPC中的应用。入选标准包括临床进展转移性PCA，嗜铬粒蛋白-A水平> 1.5倍正常上限，诊断NEPC后≥1次FDG-PET扫描，共获得23例患者。CT、PET和骨扫描上的所有转移性病灶均由两名独立的医生读取。在所有成像模式中识别出592个独特的病变，510个为骨转移，82个为软组织转移。在骨病变中，PET、CT和骨扫描分别检出22.2%、92.7%和77.6%。PET和CT对软组织病变的检出率分别为95.1%和97.5%。根据NEPC诊断的中位生存期分层，生存期<2.2年与≥2.2年的患者有更多的PET avid骨，（8 vs. 2，P=0.06）和软组织病变（7 vs. 1，P=0.01），骨（5.49 vs. 3.40，P=0.04）和软组织病变（8.02 vs. 3.90，P=0.0002）的平均SUVmax较高。在临床NEPC患者中，我们证明FDG-PET在检测转移性疾病方面具有临床实用性。除了检测之外，PET还允许治疗反应以确定肿瘤活力。随着治疗NEPC的新疗法的出现，考虑使用FDG-PET监测反应是必要的。
Fluorodeoxyglucose (FDG) positron emission tomography (PET) has well-characterized limitations in prostate adenocarcinoma (PCA). However, data assessing the utility of PET in neuroendocrine prostate cancer (NEPC) is limited to isolated case reports. Herein, we describe the first case series to assess the utility of FDG-PET in NEPC. Inclusion criteria consisted of clinically progressive metastatic PCA in the setting of a chromogranin-A levels >1.5x the upper limit of normal, and ≥1 FDG-PET scan after the diagnosis of NEPC, which yielded 23 patients. All metastatic lesions on CT, PET, and bone scan were read by two independent physicians. Five hundred ninety two unique lesions were identified across all imaging modalities, 510 were bone metastases, and 82 were soft tissue metastases. Of bone lesions, 22.2%, 92.7%, and 77.6% were detected by PET, CT, and bone scan, respectively. Of soft tissue lesions, 95.1% and 97.5% were detected by PET and CT, respectively. Stratified by the median survival from NEPC diagnosis, patients who survived <2.2 versus ≥2.2 years had more PET avid bone (8 vs. 2, P=0.06) and soft tissue lesions (7 vs. 1, P=0.01), and higher average SUVmax of bone (5.49 vs. 3.40, P=0.04) and soft tissue lesions (8.02 vs. 3.90, P=0.0002). In patients with clinical NEPC, we demonstrate that FDG-PET has clinical utility in the detection of metastatic disease. In addition to detection, PET allows for treatment response to determine tumor viability. With novel therapies on the horizon to treat NEPC, consideration to investigate the use of FDG-PET to monitor response is warranted.
登录
查看更多内容
DOI：
10.6004/jnccn.2013.0174
发表时间：
2013-12-01
影响因子：
13.4
作者：
Mohler, James L.;Kantoff, Philip W.;Ho, Maria
通讯作者：
Ho, Maria
DOI：
10.1038/modpathol.2011.56
发表时间：
2011-08
期刊：
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
影响因子：
--
作者：
通讯作者：
--
影响因子：
254.7
作者：
Siegel, Rebecca;Ma, Jiemin;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin
影响因子：
2.8
作者：
ABRAHAMSSON, PA;FALKMER, S;GRIMELIUS, L
通讯作者：
GRIMELIUS, L
影响因子：
45.3
作者：
Anker, Christopher J.;Dechet, Christopher;Shrieve, Dennis C.
通讯作者：
Shrieve, Dennis C.